Zepatier is designed to treat hepatitis C genotypes 1 and 4. The drug does not require the use of interferon, according to the report. Merck’s newly approved drug will compete with Gilead Sciences’ Harvoni and AbbVie’s Viekira Pak.
More articles on gastroenterology:
4 GI physicians in the news – Jan. 29, 2016
Proudest moments in GI: One gastroenterologist’s career high points
Sedation ups colonoscopy risk: 5 insights
